Selank – 5mg

Selank represents a breakthrough in anxiolytic peptide research. As a synthetic analog of the immunomodulatory peptide tuftsin, it retains the parent compound's immune benefits while adding profound anxiolytic and nootropic properties. The additional glyproline (PGP) motif dramatically improves metabolic stability, allowing consistent research protocols impossible with native tuftsin.

The clinical evidence is compelling. In head-to-head trials against medazepam (a benzodiazepine), Selank matched anxiolytic efficacy while adding anti-asthenic and psychostimulant benefits — the opposite of benzodiazepine sedation. Unlike classical anxiolytics, Selank shows no amnesia, cognitive impairment, tolerance, or withdrawal symptoms. This "calm without sedation" profile has made it a reference compound for anxiety research.

Mechanistically, Selank operates on multiple axes simultaneously. It modulates 52 genes related to GABA signaling — not through direct receptor agonism, but by changing receptor affinity through gene expression. It increases hippocampal BDNF (supporting neuroplasticity), inhibits enkephalin-degrading enzymes (preserving natural stress-relief peptides), and regulates inflammatory cytokines including IL-6. This multi-system approach explains both its efficacy and favorable side-effect profile.

Research applications extend well beyond anxiety. Memory studies show enhanced trace stability independent of anxiety reduction, suggesting direct nootropic effects. Pain research demonstrates prolonged enkephalin half-life through enkephalinase inhibition. Immune studies reveal regulation of 34 inflammation-related genes. For teams investigating anxiety disorders, cognitive enhancement, neuroimmune interactions, or pain modulation, Selank provides a uniquely clean, multi-target research tool with extensive clinical validation.

For research use only. Not for human consumption.